News
Merck & Co. agreed to buy respiratory drugmaker Verona Pharma Plc for around $10 billion as part of its ongoing search for ...
Zacks.com on MSN6h
Merck Faces Multiple Challenges: Will It Steer Through Successfully?MRK banks on new launches as Keytruda faces a looming patent cliff and Gardasil weakens amid China's demand slump.
Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my ...
Barchart on MSN4h
What You Need To Know Ahead of Merck's Earnings ReleaseMerck is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings dip.
Merck is acquiring Verona Pharma for $10 billion, gaining COPD drug Ohtuvayre as part of its strategy to offset Keytruda's ...
President Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S., but not immediately ...
Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...
Merck to acquire Verona Pharma for $10 billion, adding COPD drug Ohtuvayre to strengthen respiratory portfolio.
Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...
Zacks Investment Research on MSN6d
MRK Pins Hopes on New PAH Drug Winrevair Amid Looming Keytruda LOEMerck’s MRK blockbuster PD-L1 inhibitor, Keytruda, approved for several types of cancer indications, is the company's biggest ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback